Moxifloxacin Stulln Sine (Moxifloxacin)

Moxifloxacin targets bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. By inhibiting these enzymes, the drug prevents bacterial cells from multiplying, leading to a bactericidal effect that clears the infection in the ocular tissues.

The dosing regimen for Moxifloxacin Stulln Sine is determined by the prescribing ophthalmologist based on the specific infection, severity, and patient factors. The prescriber will provide instructions on the number of drops, frequency, and duration of therapy.

The safety of moxifloxacin in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Moxifloxacin belongs to the fluoroquinolone class, offering broad‑spectrum coverage against Gram‑positive and Gram‑negative ocular pathogens. Compared with older agents such as ciprofloxacin, moxifloxacin often requires fewer daily administrations and has enhanced activity against resistant strains, making it a preferred choice for many clinicians.

The product should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Do not freeze the container, and keep the vial tightly sealed when not in use.

Moxifloxacin Stulln Sine is applied topically to the eye as directed by the prescriber. Typically, one or more drops are placed in the affected eye(s) at the prescribed frequency, ensuring the eyelids are gently closed after instillation to allow adequate absorption.

Serious risks, though rare, include severe allergic reactions such as angioedema, corneal ulceration or worsening of existing corneal lesions, Stevens‑Johnson syndrome, and significant visual loss. Patients should seek immediate medical attention if they experience sudden swelling, pain, or vision changes.

Individuals with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation should avoid this product. It is also contraindicated in patients with active corneal epithelial defects unless specifically directed by an ophthalmologist.